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Author's View
Why is Drug Discovery In Vivo 
Important?
Cancer immunotherapy has made 
substantial progress over the past several 
years, such that immune-based approaches 
now provide significant benefit to a sub-
set of cancer patients, even in the face of 
advanced disease.1-5 Thus, the discovery 
and prioritization of new targets is among 
the foremost challenges for the cancer 
immunotherapy field.
The immune system represents a 
mobile army whose soldiers—the myriad 
of functionally and phenotypically spe-
cialized subsets of immune cells—con-
tinuously patrol the body for threats to 
the organism. On their journey, immune 
cells interact with diverse cell populations 
in distinct microenvironments. Effector 
T cells play a central role in antitumor 
immunity and their effectiveness depends 
on their complex interactions with both 
cancer cells and many other cell types 
in various tissue contexts. These include 
antigen-presenting cells (APCs) in the 
tumor-draining lymph nodes, tumor-vas-
culature endothelial cells, and inhibitory 
immune cells, such as tumor-infiltrating 
myeloid-derived suppressor cells. These 
complex interactions are difficult to 
model using in vitro culture systems. Our 
hypothesis is that this complexity pro-
vides many opportunities for therapeutic 
intervention, in particular for discovery of 
genes that selectively affect T-cell behavior 
in defined tissue microenvironments, such 
as occurs in tumors.
RNAi-Based Discovery  
of Negative Regulators  
of T-cell Function in Tumors
Based on these considerations, we 
devised an in vivo short hairpin RNA 
(shRNA) screening approach that enables 
investigation of candidate molecules regu-
lating T-cell behavior in particular micro-
environments, specifically tumors and 
secondary lymphoid organs.6 The study 
took advantage of pooled shRNA screen-
ing approaches that enable simultaneous 
investigation of many genes.7,8 Our goal 
was the discovery of key auto-inhibitory 
genes expressed by T cells in immuno-
suppressive tumor microenvironments. 
When T cells are activated by a microbial 
antigen in the setting of an acute infec-
tion—or in response to tumor antigens—
they undergo a fundamental change in 
cellular state switching from quiescence 
to rapid cell division and acquisition of 
effector functions. Such T-cell receptor 
driven proliferation is inhibited in tumors 
by a variety of negative signals.9,10 We 
asked which genes encode key negative 
regulators of T-cell function in tumors by 
screening for shRNAs that restored T-cell 
proliferation following tumor antigen rec-
ognition (Fig. 1).
We infected CD8+ T cells with pooled 
lentiviral shRNA libraries following brief 
in vitro culture with homeostatic cyto-
kines. Stimulation through the T-cell 
receptor (TCR)-CD3 complex was inten-
tionally avoided to prevent their differ-
entiation into effector cells. Transduced 
CD8+ T cells- derived from OT-I oval-
bumin-specific TCR transgenic mice- 
were then transferred to mice bearing 
B16 tumors that expressed ovalbumin as 
a surrogate tumor antigen. shRNAs that 
enabled T-cell accumulation in tumors 
were discovered by Illumina sequencing 
of the shRNA cassette from T cells iso-
lated from tumors and other tissues. This 
approach provided a quantitative repre-
sentation of all shRNAs in the pool and 
enabled identification of the shRNAs that 
were preferentially enriched in tumors but 
not control organs (irrelevant lymph nodes 
and spleen). Candidate T-cell inhibitory 
genes identified from the primary screen 
were validated by the creation of focused 
shRNA pools in which each putative   
T cell regulatory molecule was targeted by 
approximately 15 shRNAs. We identified 
43 genes for which at least three induced 
selective enrichment of T cells in tumors 
as compared with spleen (≥ 4-fold shRNA 
enrichment). We further investigated 
the function of Ppp2r2d (protein phos-
phatase 2, subunit B delta), a regulatory 
subunit of the PP2A family of phospha-
tases. Silencing of this gene substantially 
reduced T-cell apoptosis in tumors while 
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A key challenge facing the cancer immunology field is the discovery of the most suitable targets for therapeutic inter-
vention. we recently reported a novel rNA-interference (rNAi)-based approach for systematic discovery of such targets 
in the tumor microenvironment in vivo utilizing pooled shrNA libraries as a screening tool. here, we discuss applying this 
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concomitantly enhancing T-cell prolifera-
tion and cytokine production, biological 
effects culminating in potentiated antitu-
mor activity.6
Important Technical 
Considerations for Successful 
shRNA Screens In Vivo
There are several important technical 
considerations for the successful appli-
cation of such a screen in vivo. First, it 
is important to compare the activity of   
shRNAs across organs, including an organ 
in which little change is expected. We were 
particularly interested in shRNAs that 
were strongly enriched in tumors but not 
in irrelevant lymph nodes or the spleen. 
Since shRNAs within a given library may 
vary in relative abundance, the plotting of 
the shRNA levels in the organ or tissue of 
interest, in this case, in tumors, relative to 
a control organ (e.g., the spleen) addresses 
this technical issue. Second, each shRNA 
should be represented many times in the 
relevant organ for reproducible results. 
We aimed for > 100-fold representation 
of each shRNA among tumor-infiltrating 
T cells. This tissue limits the total num-
ber of shRNAs that can be analyzed in a 
given experiment. We assayed up to ~1000 
shRNAs per pool, and 15 recipient mice 
(per pool) were used to generate sufficient 
numbers of T cells for DNA isolation and 
deep sequencing of the integrated shRNA 
cassette, as well as to reduce potential vari-
ability among mice. It may be feasible to 
utilize larger number of shRNAs per pool, 
depending on the design of the screen. 
Third, a large number of control shRNAs 
within each pool are absolutely essential to 
assess the frequency of off-target effects.
Future Applications in 
Immunotherapeutic Discovery
We believe that there are many appli-
cations for this non-biased approach, both 
in the investigation of immune cell func-
tion in specific tissue microenvironments 
in vivo, as well as in the discovery of new 
therapeutic targets. This general approach 
should be amenable to the study of other 
important immune cell populations in 
a physiological context and to discover 
genes that control key aspects of behavior 
in vivo, including survival, tissue hom-
ing, activation, and (or) acquisition of key 
effector functions. Considering the inte-
gral involvement of these cell properties 
in immunity, there are also exciting appli-
cations for our screening method in the 
development of novel cancer immunother-
apies. A major application is the discovery 
of shRNAs that enhance the therapeutic 
activity of adoptively transferred human T 
cells. To this end, we have initiated such 
efforts and experiments are underway 
using human T cells in a xenotransplanta-
tion model. Our approach may also impact 
the field by guiding the pursuit of selected 
targets for the development of antibody or 
small molecule based inhibitors, depend-
ing on their cellular localization and 
Figure 1. in vivo shrNA screen for the discovery of negative regulators of t-cell function in tumors. 
(A) ovalbumin (ova)-specific t cells were infected with pooled shrNA libraries encoded in a lenti-
viral vector prior to being injected into mice bearing B16-ova melanomas. (B) shrNAs that attenu-
ated key negative regulators relieved t cell inhibition, thereby enabling substantial t-cell expansion 
preferentially within tumors in response to tumor-antigen recognition. (C) Deep sequencing of 
the shrNA cassette from purified t cells provided a quantitative representation of all shrNAs in 
the pool across different tissues. shrNAs enabling t-cell proliferation in tumors were substantially 












































function. We believe that the discovery of 
therapeutic targets on the basis of studies 
performed in vivo will provide new and 
exciting avenues for the development of 
cancer immunotherapeutics.
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